Sajjad Mueed, MD

Sajjad Mueed, MD

Associate Professor, Department of Neurology, Director, Comprehensive Stroke Center at Memorial Medical
Neuroscience Institute
Languages:
English, Urdu

    About me

    Dr. Mueed, is an Associate Professor in the Department of Neurology at SIU School of Medicine and SIU Medicine.  Dr. Mueed is the Director of the Comprehensive Stroke Center at Memorial Medical Center.  Dr. Mueed is a neurologist who specializes in stroke, electrodiagnosis and sleep, and neurorehabilitation.  Dr. Mueed is board certified in American Board of Psychiatry and Neurology (Neurology), American Board of Psychiatry and Neurology (Clin. Neurophys.), American Board of Sleep Medicine, American Board of Psychiatry and Neurology (Vascular Neurology), American Board of Electrodiagnostic Medicine, American Board of Psychiatry and Neurology (Sleep Medicine), United Council for Neurologic Subspecialties (UCNS) Certified in Neuroimaging, United Council for Neurologic Subspecialties (UCNS) Certified in Neural Repair and Rehabilitation.

    Gender

    Male

    Additional languages spoken

    Urdu

    Education & training

    Positions
    Director, Memorial Medical Center Stroke Center
    Neurologist
    Board Certifications
    Neurology
    Neural Repair and Rehabilitation
    Neuroimaging
    Internal Medicine
    Sleep Medicine
    Clinical Neurophysiology
    Vascular Neurology
    Electrodiagnostic Medicine
    Medical School
    Quaid-e-Azam Medical College in Bahawalpur, Pakistan
    Residency
    SIU School of Medicine, Springfield, IL - Neurology
    Fellowship
    SIU School of Medicine, Springfield, IL - Epilepsy & Clinical Neurophysiology and Stroke

    Academic Location

    Academic Office

    751 N Rutledge St Springfield, IL 62702
    Mail Code: 9643
    Go to map

    Contact Info

    217-545-8684

    Research

    Research Interests
    Stroke Specialist, Sleep Disorders, Vascular Neurology, Electro diagnostic Medicine, and Clinical Neurophysiological Studies.

    Clinical trials

    Trial
    Neuroscience Institute

    Sleep for Stroke Management and Recovery Trial

    Active recruiting

    The primary goals of this study are to determine whether treatment of obstructive sleep apnea with positive airway pressure starting shortly after accute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event and (2) improves stroke outcomes at 3 months in patients who experienced ischemic stroke.

    Contact: Stephanie Kohlrus 217-545-3013
    Trial
    Neuroscience Institute

    18-513: A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor XA Inhibitor

    Active not recruiting

    18-513:  The purpose of this study is to evaluate the effect of andexanet alfa (andexanet) versus usual care on the rate of effective homostasis.

    Contact: Stephanie Kohlrus 217-545-3013
    Trial
    Neurology

    A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    Active recruiting

    The primary objective is to assess the effect of XEN1101 versus placebo on reducing PGTCS frequency in subjects with PGTCS.

    Contact: Stephanie Kohlrus 217-545-3013
    Trial
    Neurology

    A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures

    Active recruiting

    The primary objective of this study is to assess the effect of XEN1101 versus placebo on reducing focal seizure frequency.

    Contact: Stephanie Kohlrus 217-545-3013
    Trial
    Neurology

    An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

    Active recruiting

    The primary endpoint of this study is to evaluate the long-term safety and tolerability of Staccato alprazolam.

    Contact: Rylee Manka 217-545-1394
    Trial
    Neurology

    A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

    Active recruiting

    The purpose of this study is to compare the success of a single admnistration of Staccato alprazolam compared with placebo in rapidly terminating a seizure episode within 90seconds after IMP administration.

    Contact: Rylee Manka 217-545-1394